NLS-FMAU is similar to one of the basic units of DNA (thymidine) and optimized for use as an imaging agent. Our imaging agent is incorporated into the DNA of dividing cells and has a passenger attached, F-18. This is a form of fluorine that contains low radioactive dosage, and as it decays, emits energy from the tumor to which it is bound. This energy is detected by a specialized medical imaging camera called Positron Emission Tomography, or what is commonly called a PET scanner. There are over 5,500 PET scanners in the United States being used in hospitals right.

The goal of our NLS-FMAU imaging agent is to provide the answer to a fundamental question in cancer management: Is the therapy working?  NuView’s imaging agent can rapidly provide information to determine if the cancer cells are still proliferating after the administration of a particular therapy or if they have stopped.   This product may assist in validating a current dosage level or therapy and provide rapid flexibility for adjustments or switching therapies.  Rapid assessment of a current therapy provides the essential time needed for optimal treatment of the disease.


NuView has licensed this imaging biomarker from Peter S. Conti, MD, PhD, at the University of Southern California, and is developing NLS-FMAU to revolutionize the assessment of cancer treatments.  Dr. Conti is a field leader, past President of the Society of Nuclear Medicine and Medical Director of NuView.